Status:
COMPLETED
Safety Study of JTT-302 in Subjects With Low HDL-C Levels
Lead Sponsor:
Akros Pharma Inc.
Conditions:
Dyslipidemia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety of JTT-302 when administered for eight or 12 weeks in subjects with low HDL-C levels and to determine the effect of JTT-302 on lipid parameters and ...
Eligibility Criteria
Inclusion
- Subjects must have successfully completed the 4-week treatment period of study AT302-U-06-003
Exclusion
- Females who are pregnant or lactating, and females of child bearing potential who are not using an effective method of contraception
- Use of Cytochrome P450 3A4 inducers or inhibitors, as defined in the protocol
- Subjects who cannot follow the prescription and OTC medication restrictions defined in the protocol
- Flu-shots not permitted during the study, including the follow-up period.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT00748852
Start Date
January 1 2007
End Date
March 1 2008
Last Update
February 4 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Santa Ana, California, United States